Jun 22, 2020
Akebia Therapeutics Launches AkebiaShares, a Peer-to-Peer Educational Program Series for the Renal Community
Jun 18, 2020
Akebia Therapeutics Announces New Chief Financial Officer
May 26, 2020
Akebia Therapeutics to Present at Jefferies Virtual Global Healthcare Conference
May 21, 2020
Akebia Therapeutics Announces Change to Virtual Annual Meeting of Stockholders
May 19, 2020
Akebia Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
May 11, 2020
Akebia Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
May 11, 2020
Akebia Therapeutics Announces Proposed Public Offering of Common Stock
May 05, 2020
Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Financial Results
May 05, 2020
Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
May 04, 2020
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 28, 2020
Akebia Therapeutics to Report First Quarter 2020 Financial Results and Discuss Recent Business Highlights
Apr 07, 2020
Akebia Therapeutics Appoints Myles Wolf, M.D., M.M.Sc., Chief of Nephrology and Professor at Duke University School of Medicine, to Board of Directors
Apr 02, 2020
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 23, 2020
Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference